Stenocare AS
Stenocare A/S cultivates, produces, imports, distributes, and sells prescription-based medical cannabis products to patients in Denmark and internationally. It offers medical cannabis oil products, including THC, THC/CBD, and CBD oil products. The company was incorporated in 2017 and is based in Randers, Denmark.
Stenocare AS (STENO) - Net Assets
Latest net assets as of December 2025: Dkr9.55 Million DKK
Based on the latest financial reports, Stenocare AS (STENO) has net assets worth Dkr9.55 Million DKK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr12.64 Million) and total liabilities (Dkr3.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr9.55 Million |
| % of Total Assets | 75.55% |
| Annual Growth Rate | -10.32% |
| 5-Year Change | -76.27% |
| 10-Year Change | N/A |
| Growth Volatility | 128.58 |
Stenocare AS - Net Assets Trend (2018–2025)
This chart illustrates how Stenocare AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Stenocare AS (2018–2025)
The table below shows the annual net assets of Stenocare AS from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr9.55 Million | +374.88% |
| 2024-12-31 | Dkr-3.47 Million | -113.45% |
| 2023-12-31 | Dkr25.82 Million | +6.96% |
| 2022-12-31 | Dkr24.14 Million | -40.01% |
| 2021-12-31 | Dkr40.24 Million | -23.45% |
| 2020-12-31 | Dkr52.57 Million | +290.15% |
| 2019-12-31 | Dkr13.47 Million | -34.18% |
| 2018-12-31 | Dkr20.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Stenocare AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 927704500.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr6.00 Million | 63.35% |
| Common Stock | Dkr3.47 Million | 36.65% |
| Total Equity | Dkr9.47 Million | 100.00% |
Stenocare AS Competitors by Market Cap
The table below lists competitors of Stenocare AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Semilux International Ltd. Ordinary Shares
NASDAQ:SELX
|
$4.04 Million |
|
URU METALS LTD
F:NVRA
|
$4.04 Million |
|
Dynaciate Group Bhd
KLSE:5178
|
$4.04 Million |
|
paragon GmbH & Co. KGaA
F:PGN
|
$4.04 Million |
|
VIOL Co. Ltd
KQ:335890
|
$4.04 Million |
|
Acrux Limited
PINK:ARUXF
|
$4.04 Million |
|
Marvel Biosciences Corp.
PINK:MBCOF
|
$4.03 Million |
|
Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
|
$4.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Stenocare AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,473,687 to 9,473,052, a change of 12,946,739.
- Net loss of 2,390,440 reduced equity.
- Other factors increased equity by 15,337,179.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr-2.39 Million | -25.23% |
| Other Changes | Dkr15.34 Million | +161.9% |
| Total Change | Dkr- | % |
Book Value vs Market Value Analysis
This analysis compares Stenocare AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.49x to 4.56x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Dkr2.03 | Dkr1.00 | x |
| 2019-12-31 | Dkr1.34 | Dkr1.00 | x |
| 2020-12-31 | Dkr4.72 | Dkr1.00 | x |
| 2021-12-31 | Dkr3.33 | Dkr1.00 | x |
| 2022-12-31 | Dkr2.00 | Dkr1.00 | x |
| 2023-12-31 | Dkr1.85 | Dkr1.00 | x |
| 2024-12-31 | Dkr-0.10 | Dkr1.00 | x |
| 2025-12-31 | Dkr0.22 | Dkr1.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Stenocare AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -34.05%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.33x
- Recent ROE (-25.23%) is above the historical average (-27.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -16.00% | -79.05% | 0.19x | 1.06x | Dkr-5.32 Million |
| 2019 | 12.63% | 19.38% | 0.28x | 2.35x | Dkr354.96K |
| 2020 | -22.42% | -5939.17% | 0.00x | 1.07x | Dkr-17.04 Million |
| 2021 | -31.64% | -808.41% | 0.04x | 1.09x | Dkr-16.76 Million |
| 2022 | -67.53% | -363.13% | 0.11x | 1.64x | Dkr-18.72 Million |
| 2023 | -68.04% | -467.55% | 0.10x | 1.48x | Dkr-20.15 Million |
| 2024 | 0.00% | -1545.07% | 0.11x | 0.00x | Dkr-34.14 Million |
| 2025 | -25.23% | -34.05% | 0.56x | 1.33x | Dkr-3.34 Million |
Industry Comparison
This section compares Stenocare AS's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
No peer company data available for comparison.